- Home
- KRYS vs FCFS Comparison
KRYS vs FCFS Comparison
Compare KRYS & FCFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- FCFS
- Stock Information
- Founded
- KRYS 2015
- FCFS 1988
- Country
- KRYS United States
- FCFS United States
- Employees
- KRYS N/A
- FCFS N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- FCFS Other Specialty Stores
- Sector
- KRYS Health Care
- FCFS Consumer Discretionary
- Exchange
- KRYS Nasdaq
- FCFS Nasdaq
- Market Cap
- KRYS 6.3B
- FCFS 6.7B
- IPO Year
- KRYS 2017
- FCFS 1991
- Fundamental
- Price
- KRYS $221.08
- FCFS $159.15
- Analyst Decision
- KRYS Strong Buy
- FCFS Strong Buy
- Analyst Count
- KRYS 9
- FCFS 4
- Target Price
- KRYS $214.22
- FCFS $168.75
- AVG Volume (30 Days)
- KRYS 335.7K
- FCFS 291.2K
- Earning Date
- KRYS 11-03-2025
- FCFS 10-30-2025
- Dividend Yield
- KRYS N/A
- FCFS 1.06%
- EPS Growth
- KRYS 275.72
- FCFS 27.90
- EPS
- KRYS 6.66
- FCFS 6.92
- Revenue
- KRYS $373,164,000.00
- FCFS $3,486,435,000.00
- Revenue This Year
- KRYS $34.33
- FCFS $8.28
- Revenue Next Year
- KRYS $48.04
- FCFS $10.44
- P/E Ratio
- KRYS $32.83
- FCFS $22.91
- Revenue Growth
- KRYS 54.51
- FCFS 3.86
- 52 Week Low
- KRYS $122.80
- FCFS $100.24
- 52 Week High
- KRYS $221.84
- FCFS $166.08
- Technical
- Relative Strength Index (RSI)
- KRYS 76.21
- FCFS 55.53
- Support Level
- KRYS $203.17
- FCFS $146.95
- Resistance Level
- KRYS $212.97
- FCFS $158.71
- Average True Range (ATR)
- KRYS 7.05
- FCFS 4.84
- MACD
- KRYS 0.96
- FCFS -0.48
- Stochastic Oscillator
- KRYS 98.60
- FCFS 74.55
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.